Answers are grounded in this paper and cite their sources.
Retrospective study evaluates efficacy and safety of ustekinumab biosimilar in Crohn’s Disease, suggesting positive outcomes for patients.
Background Ustekinumab biosimilar has been approved for the treatment of Crohn’s Disease (CD). While clinical trial data are available from studies conducted in psoriasis populations, there is a paucity of real-world evidence evaluating the efficacy and safety associated with switching from originator ustekinumab or initiating biosimilar in ustekinumab-naïve patients. Methods This bicentric retrospective study included two groups: (a) CD patients who switched from originator ustekinumab (Stelara) to a biosimilar (SB17 [Pyzchiva®] or AVT04 [Uzpruvo®]); and (b) ustekinumab-naive patients starting a biosimilar. Inclusion required at least three months of follow-up, while those with ulcerative colitis, postoperative CD prophylaxis, or combination therapy were excluded. The primary outcome for switchers was drug persistence; for naive patients, short-term clinical response at 3–4 months. Clinical, biochemical, and safety data were collected at baseline, 3–4 months, and 6 months. Results A total of 74 patients were included, forty-one patients were UST-switch, and 30 patients were UST-naive. In the UST-switch cohort, 37 patients switched to ustekinumab SB17 (Pyzchiva ®) and 4 patients to AVT04 (Uzpruvo®). No differences were observed in the mean IHB pre-switch and 3 months after the switch (2.4 vs 2.2, Δ -0.2 95% CI -1.3-1; p = 0.8) nor at 6 months follow-up (2.4 vs 2.1, Δ -0.2 95% CI -1.4-1; p = 0.7). Trough levels pre-switch and 3 months after the switch were comparable (5 vs 6.2, Δ -1.3 95% CI -3.1-0.48). Fecal calprotectin was comparable at baseline and 3 months post-switch (181.7 vs 148.7; Δ -33.1 95% CI -148.6-82.4; p = 0.6). At 6 months post-switch, the Ustekinumab biosimilar persistence was 94.5% (95% CI 81-98.7) (figure 1A). One dermatological adverse event was detected 2.4%). For UST-initiation cohort, all patients initiated SB17 (Pyzchiva ®). At 3-4 months, 21 patients (70%) achieved steroid-free clinical remission and 24 patients (80%) steroid-free clinical response. At 6 months, 16 patients (80%) achieved steroid-free clinical remission, and 18 patients (90%) achieved steroid-free clinical response. No difference was observed in the fecal calprotectin from baseline and at 3-4 months (224.8 vs 223.6; Δ 1.23; 95% CI -232.5-234.9). No adverse event was observed. Conclusion Administration of the ustekinumab biosimilar appears to be both safe and effective when initiated in UST-naive patients or following switch from originator ustekinumab in CD patients. Conflict of interest: Fuentes-Valenzuela, Esteban: Esteban Fuentes-Valenzuela has received education funding from AbbVie, Alfa Sigma Pfizer, Takeda, DrFalk Pharma, Kern Pharma and Janssen and served as speaker for Janssen Chivato Martín Falquina, Irene: I have received financial support from AbbVie, Kern, Takeda, and Janssen for postgraduate courses and attendance at scientific conferences. Olmos Jerez, Jose Antonio: No conflict of interest Lopez Martin, Maria Del Carmen: No conflict of interest Calvache Rodriguez, Almudena: No conflict of interest Gil Santana, Marina: No conflict of interest Somoza Fernández, Beatriz: No conflict of interest Castaño Milla, Carlos: No conflict of interest Bejerano Dominguez, Alicia: No conflict of interest
No takes yet. Share an insight, caveat, or question.
Fuentes-Valenzuela et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: